UniQure up for sale?

The gene therapy company UniQure, whose shares have shot up 151% this year, is considering a sale, according to Bloomberg. No financial decision has been made, but UniQure would be only the latest gene therapy firm to find a suitor. Among other deals, Nightstar Therapeutics was acquired by Biogen earlier this year; Roche said last year it would pick up Spark Therapeutics.

The pipeline at UniQure, a Netherlands-based company, includes experimental treatments for hemophilia and Huntington’s disease, among other rarer diseases.